Mr. Cooper Group Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mr. Cooper Group Inc. - overview
Established
2003
Location
Buffalo, NY-New York, US
Primary Industry
Biotechnology
About
Athenex, Inc. is a biopharmaceutical company dedicated to developing innovative therapies, particularly in oncology, to improve treatment efficacy and safety for cancer patients. Founded in 2003 in Buffalo, US, Athenex, Inc. specializes in oncology therapeutics.
The company has undergone strategic pivots, including a focus on proprietary drug formulations. Its founders, Brittany Gerber and Lyn Dyster, have contributed to its innovative approach. The CEO is Johnson Lau. Athenex has participated in 21 deals, with its most recent funding round, a Private Placement/Follow on, concluding on January 24, 2018, raising a total of USD 65.
58 mn. Athenex specializes in the development and commercialization of innovative therapeutics, particularly in the oncology sector. The company’s core product offerings include its proprietary drug formulations, designed to enhance the efficacy and safety of cancer treatments. Athenex targets significant unmet medical needs in oncology by providing solutions that improve patient outcomes while minimizing adverse effects.
Its products cater primarily to healthcare providers, including hospitals and specialty clinics, with a focus on oncologists and their patients, marketed across North America and select regions in Europe. For the year 2022, Athenex reported a revenue of USD 102. 82 mn and an EBITDA of USD -63. 33 mn.
The company generates revenue through product sales and collaborations with pharmaceutical partners, supplying proprietary formulations to healthcare providers and institutions, ensuring efficient distribution of their oncology products. Athenex plans to leverage the funding raised in its most recent deal on January 24, 2018, to support a global manufacturing strategy. This strategy includes the development and launch of new oncology products, with the aim of expanding into new markets, specifically targeting regions in Europe and Asia by 2025. The company has also filed for Chapter 11 bankruptcy protection in May 2023, which may influence its growth trajectory.
Current Investors
Mandra Capital, Western New York Business Development Fund, The Niagara Region Ventures Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.athenex.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Mr. Cooper Group Inc. - timeline of key events
Mr. Cooper Group Inc. - financials
| Fiscal Year Ended | Dec 30, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 20,600,000 | 38,043,000 | 89,100,000 | 101,229,000 | - | - | - |
| % Revenue Growth (YoY) | - | 84.7% | 134.2% | 13.6% | - | - | - |
| EBITDA (USD) | (84,300,000) | (102,966,000) | (123,035,000) | (114,689,000) | - | - | - |
| Operating Income (USD) | - | (109,988,000) | (126,818,000) | (119,532,000) | - | - | - |
| Operating Margin | - | (289.1%) | (142.3%) | (118.1%) | - | - | - |
| % EBITDA Margin | (409.2%) | (270.7%) | (138.1%) | (113.3%) | - | - | - |
| NET Income (USD) | (87,700,000) | (131,396,000) | (128,711,000) | (125,533,000) | - | - | - |
| % Net Margin | (425.7%) | (345.4%) | (144.5%) | (124.0%) | - | - | - |
Mr. Cooper Group Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bankruptcy/Write-off | Completed | Mr. Cooper Group Inc. | - | ||||||||
| Buyout | Announced | U.S. and European Royalty and Milestone Interests in Klisyri | - | ||||||||
| Add-on, Trade Sale | Completed | Cell Medica Tcr Limited | - | ||||||||
| Venture Debt | Completed | Mr. Cooper Group Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Mr. Cooper Group Inc. | - |
Displaying 1 - 5 of 23
Mr. Cooper Group Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.